You just read:

Phase 2b Data Suggest ReVision's Oral Fenretinide (RT-101) Slows Lesion Growth, Preserves Vision and Reduces Incidence of Neovascularization in Geographic Atrophy Patients

News provided by

ReVision Therapeutics Inc.

Oct 18, 2010, 08:00 ET